ABIGAIL WOODRUFF: Open Payments
NPI 1740903731 · CONYERS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,612 in 146 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $1,316 · 2025 $2,612
Food & beverage: $2,552Education: $60
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 30 | $511 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 24 | $297 |
| Janssen Biotech, Inc. | 11 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $242 |
| Phathom Pharmaceuticals, Inc. | 18 | $228 |
| Ardelyx, Inc. | 12 | $177 |
| Madrigal Pharmaceuticals | 5 | $142 |
| VIVUS LLC | 9 | $140 |
| PFIZER INC. | 6 | $122 |
| Lilly USA, LLC | 5 | $102 |
Products named: XIFAXAN, TREMFYA, RINVOQ, ENTYVIO, VOQUEZNA, IBSRELA, REZDIFFRA, DUPIXENT.
Industry payments across GA — which companies pay providers there.
